SCYNEXIS (SCYX)

• Market cap: $34.6M
• 1 day: 3.01%
• 5 days: 3.15%
• 1 month: -3.26%
• 3 months: -27.88%
• 6 months: -41.64%
• Year to date: -38.82%
• 1 year: -43.85%
• 5 years: -90.66%
• 10 years: -99.03%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Employees: 29

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

100% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 8

11% more funds holding

Funds holding: 44 [Q3] → 49 (+5) [Q4]

2.93% less ownership

Funds ownership: 34.77% [Q3] → 31.84% (-2.93%) [Q4]

25% less capital invested

Capital invested by funds: $19.6M [Q3] → $14.6M (-$4.99M) [Q4]